ArticleScientific reports2024
The clinical relevance of a polygenic risk score for type 2 diabetes mellitus in the Korean population.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Preimplantation genetic testing for polygenic diseases: A novel paradigm in embryo selection.Biochemistry and biophysics reports · 2026Review
- Predicting incident type 2 diabetes using wearable activity and polygenic risk: A survival-modeling study in All of Us.The Journal of clinical endocrinology and metabolism · 2026Article
- Interplay between obesity-associated insulin resistance and immune system through the lens of evolutionary medicine.Molecular metabolism · 2026Review
- Real-World Utility of GWAS-Based Diabetes Mellitus Panel Testing.International journal of molecular sciences · 2025Article
- Transferability of polygenic risk scores for metabolic and cardiovascular traits in an underrepresented population.NPJ genomic medicine · 2025Article
- Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and older.Diabetes, obesity & metabolism · 2025Article
- Genetic risk and polygenic risk score assessment of prediabetes and progression to type 2 diabetes.Diabetes, obesity & metabolism · 2025Article
- Clinical use of polygenic scores in type 2 diabetes: challenges and possibilities.Diabetologia · 2025Review
- Cumulative exposures to glycaemia and lipids are associated with coronary artery disease in type 1 diabetes: a call for action.Cardiovascular diabetology · 2025Article
- XPRS: a tool for interpretable and explainable polygenic risk score.Bioinformatics (Oxford, England) · 2025Article
- Integrating Polygenic Risk Scores (PRS) for Personalized Diabetes Care: Advancing Clinical Practice with Tailored Pharmacological Approaches.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Review
- Gene variations and sweet taste sensitivity in Zambian adults with and without type 2 diabetes mellitus.PloS one · 2025Article
- Mechanism-free repurposing of drugs for C9orf72-related ALS/FTD using large-scale genomic data.Cell genomics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
Abstract
The clinical utility of a type 2 diabetes mellitus (T2DM) polygenic risk score (PRS) in the East Asian population remains underexplored. We aimed to examine the potential prognostic value of a T2DM PRS and assess its viability as a clinical instrument. We first established a T2DM PRS for 5490 Korean individuals using East Asian Biobank data (269,487 samples). Subsequently, we assessed the predictive capability of this T2DM PRS in a prospective longitudinal study with baseline data and data from seven additional follow-ups. Our analysis showed that the T2DM PRS could predict the transition of glucose tolerance stages from normal glucose tolerance to prediabetes and from prediabetes to T2DM. Moreover, T2DM patients in the top-decile PRS group were more likely to be treated with insulin (hazard ratio = 1.69, p value = 2.31E-02) than were those in the remaining PRS groups. T2DM PRS values were significantly high in the severe diabetes subgroup, characterized by insulin resistance and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.